Literature DB >> 36148162

Treatment with cefiderocol in K. pneumoniae KPC nosocomial external ventricular drainage meningitis: A brief report.

Francesco Colombo1, Ali Waheed1, Sandro Panese2, Claudio Scarparo3, Maria Solinas3, Saverio Giuseppe Parisi1, Nicholas Geremia2.   

Abstract

We report the case of successful use of cefiderocol (FDC) in a Carbapenemase Producing K. pneumoniae (CPKP) post-surgical meningitis in a 44-year-old man treated with antimicrobial therapy and external ventricular drainage (EVD). The patient was known for being colonised by CPKP; for this reason, therapy with ceftazidime/avibactam (CZA) plus fosfomycin and linezolid was started. After an initial response a CZA resistant CPKP strain was isolated from CSF culture, so the antibiotic therapy was modified to FDC with trimethoprim/sulfamethoxazole for 14 days, and EVD was replaced. A complete recovery was obtained. This is the first case report describing FDC administration in CPKP meningitis.
Copyright © 2016 - 2022 InfezMed.

Entities:  

Keywords:  Klebsiella pneumoniae; carbapenemase; cefiderocol; enterobacterales; meningitidis

Year:  2022        PMID： 36148162      PMCID： PMC9448310          DOI： 10.53854/liim-3003-15

Source DB:  PubMed          Journal:  Infez Med        ISSN： 1124-9390


  11 in total

1.  Trends in Klebsiella pneumoniae strains isolated from the bloodstream in a teaching hospital in southern Italy.

Authors:  Raffaele Del Prete; Luigi Ronga; Grazia Addati; Raffaella Magrone; Angela Abbasciano; Marilú Decimo; Adriana Mosca; Giuseppe Miragliotta
Journal:  Infez Med       Date:  2019-03-01

2.  Update on the main MDR pathogens: prevalence and treatment options.

Authors:  Silvano Esposito; Giuseppe De Simone
Journal:  Infez Med       Date:  2017-12-01

Review 3.  Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing.

Authors:  Paolo Gaibani; Tommaso Giani; Federica Bovo; Donatella Lombardo; Stefano Amadesi; Tiziana Lazzarotto; Marco Coppi; Gian Maria Rossolini; Simone Ambretti
Journal:  Antibiotics (Basel)       Date:  2022-05-06

Review 4.  Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.

Authors:  Chuanhai Wang; Deqing Yang; Yifan Wang; Wentao Ni
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

5.  Antibiotic resistance patterns and prevalence of class I, II and III Integrons among clinical isolates of Klebsiella pneumoniae.

Authors:  Abasali Delarampour; Zahra Rashki Ghalehnoo; Farzad Khademi; Hamid Vaez
Journal:  Infez Med       Date:  2020-03-01

Review 6.  Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology.

Authors:  Maxwell J Lasko; David P Nicolau
Journal:  Curr Infect Dis Rep       Date:  2020-02-07       Impact factor: 3.725

7.  Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin.

Authors:  Takayuki Katsube; Roger Echols; Toshihiro Wajima
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

8.  Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections.

Authors:  Marianna Meschiari; Sara Volpi; Matteo Faltoni; Giovanni Dolci; Gabriella Orlando; Erica Franceschini; Marianna Menozzi; Mario Sarti; Giovanni Del Fabro; Benedetta Fumarola; Francesco Guarneri; Paola Lanza; Silvia Lorenzotti; Barbara Saccani; Liana Signorini; Evelyn Van Hauwermeiren; Milo Gatti; Federico Pea; Francesco Castelli; Cristina Mussini
Journal:  JAC Antimicrob Resist       Date:  2021-12-11

9.  Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.

Authors:  Takayuki Katsube; David P Nicolau; Keith A Rodvold; Richard G Wunderink; Roger Echols; Yuko Matsunaga; Anju Menon; Simon Portsmouth; Toshihiro Wajima
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.790

Review 10.  Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol.

Authors:  Muhammad Bilal; Lobna El Tabei; Sören Büsker; Christian Krauss; Uwe Fuhr; Max Taubert
Journal:  Clin Pharmacokinet       Date:  2021-08-22       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.